BioMarin Pharmaceutical Inc.

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
80.91 ^USD	-1.53%		-8.71%	-16.09%

Apr. 25	Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $85 From $83, Maintains Sector Perform Rating	MT
Apr. 25	Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating	MT

BioMarin Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 22, 2024 at 04:07 pm EST

BioMarin Pharmaceutical Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 646.21 million compared to USD 537.54 million a year ago. Net income was USD 20.38 million compared to net loss of USD 0.249 million a year ago.

Basic earnings per share from continuing operations was USD 0.11. Diluted earnings per share from continuing operations was USD 0.11.

Latest news about BioMarin Pharmaceutical Inc.

Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $85 From $83, Maintains Sector Perform Rating	Apr. 25	MT
Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating	Apr. 25	MT
Transcript : BioMarin Pharmaceutical Inc., Q1 2024 Earnings Call, Apr 24, 2024	Apr. 24
BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours	Apr. 24	MT
(BMRN) BIOMARIN PHARMACEUTICAL Forecasts Fiscal Year 2024 EPS Range $2.75 - $2.95	Apr. 24	MT
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $648.8M	Apr. 24	MT
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 EPS $0.71	Apr. 24	MT
BioMarin Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says	Apr. 22	MT
Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing	Apr. 15	MT
Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing	Apr. 01	MT
Transcript : BioMarin Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 01:35 PM	Mar. 12
BioMarin Pharmaceutical Says Voxzogo Leads to Height Gains in Children With Achondroplasia	Mar. 12	MT
Transcript : BioMarin Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:40 AM	Mar. 11
Biomarin Pharmaceutical Insider Sold Shares Worth $348,280, According to a Recent SEC Filing	Mar. 07	MT
BioMarin Pharmaceutical Appoints Cristin Hubbard as Chief Commercial Officer	Mar. 07	MT
Biomarin Announces Board Changes, Effective May 20, 2024	Mar. 07	CI
Transcript : BioMarin Pharmaceutical Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 12:50 PM	Mar. 05
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- Update	Feb. 26	DJ
BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies	Feb. 26	RE
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme	Feb. 26	DJ
BioMarin Pharma gets DOJ subpoena on certain drug testing programs	Feb. 26	RE
Wedbush Adjusts BioMarin Pharmaceutical's PT to $80 From $78, Keeps Neutral Rating; Continues to See Limited Upside	Feb. 23	MT
Transcript : BioMarin Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
BioMarin Pharmaceutical Q4 Adjusted Earnings, Revenue Rise, 2024 Outlook Set -- Shares Decline After Hours	Feb. 22	MT

Chart BioMarin Pharmaceutical Inc.

Duration

Period

More charts

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Sector

Pharmaceuticals

Calendar

2024-05-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

80.91 USD

Average target price

110 USD

Spread / Average Target

+35.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.35B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B

Biopharmaceuticals